Search Videos and More
Course
Cardiotoxic Therapies in Cancer Treatment: What Providers Need to Know
Thanks to advances in treatment, more people are surviving cancer and living into their 60s, 70s, and beyond. But with this increase in survival has also come an increase in cardiovascular disease for this population. As a result, providers must keep cardiotoxicity in mind as they implement treatment plans for their patients, says Eman Hamad, MD, director of Cardio-Oncology and the Advanced Heart Failure and Transplant Program at Temple University Hospital.
Course
Interstitial Lung Disease (ILD) and Associated Pulmonary Hypertension
Interstitial lung disease (ILD) is a commonly encountered disease state. Patients who develop ILD associated with pulmonary hypertension have an increased mortality risk. This program aims to review the classification of commonly encountered interstitial lung diseases. Secondly, to describe the pathophysiology that leads to the development of ILD associated pulmonary hypertension. Lastly, to review a diagnostic approach to ILD associated pulmonary hypertension along with treatment options.
Course
Cardiac Amyloidosis: What Providers Should Know About Screening, Diagnosis, and Treatment
Over the past two decades there has been a significant increase in both the incidence and prevalence of cardiac amyloidosis. This is most likely due to improved screening and diagnosis. However, even with these advances, delayed diagnosis is common. Diagnosis typically takes two years for patients with amyloid light-chain amyloidosis (AL), and up to 7.2 years for those with transthyretin amyloidosis (ATTR), explains Temple heart failure cardiologist Carly Fabrizio, DO.
News
Temple Lung Center | Enrolling Clinical Trials
The Temple Lung Center conducts one of the most comprehensive lung disease clinical trials programs in the country. Our advancements in basic, translational and clinical research are changing lung disease treatment. By pioneering effective therapies, we bring hope to patients with serious and debilitating lung diseases.
News
Temple Lung Center: Advancing Research in COPD
The Temple Lung Center is one of the world’s largest COPD research centers, and has demonstrated its commitment to offer innovative therapies to patients by applying research breakthroughs to clinical care.
Video
Lung Transplantation for COPD Patients
Chronic Obstructive Pulmonary Disease (COPD) is the sixth leading cause of death in the U.S., affecting nearly 16 million adults. Dr. Gerard Criner, Director of the Temple Lung Center, recently joined the Global Forum on Lung Transplantation to explore the role of lung transplantation for COPD.
News
November Quarterly Impact Report: The Temple Healthy Chest Initiative
The American Cancer Society is forecasting more than two million new cases of cancer to be diagnosed in the year 2024. And while the incidence rate is on the rise, cancer-related deaths continue to decline. Early detection is key to producing better outcomes for patients.
Course
Understanding Hemodynamic Profiles in Heart Failure
Managing heart failure requires a comprehensive approach that integrates multiple sources of information, rather than relying on a single data set, says Paul Forfia, MD, co-director of Pulmonary Hypertension, Right Heart Failure & CTEPH Program at Temple University Hospital.
News
Temple Lung Center: Advancing Research in ILD
Interstitial lung diseases (ILD) significantly impact patient morbidity and mortality. As an ILD Center of Excellence, the Temple Lung Center has established comprehensive programs for the evaluation and management of patients with a wide range of ILDs. This includes extensive clinical research and lung transplantation expertise.
Course
Diagnosing the Apical Variant of Hypertrophic Cardiomyopathy
A 60-year-old man with a history of hypertension was admitted to the hospital after three days of a drooping face and right arm weakness. He had no chest pain or shortness of breath, and no prior history of irregular heartbeat. However, his echocardiogram was abnormal, and his high sensitivity troponin level was mildly to moderately elevated. Doctors ordered STAT echocardiogram with saline contrast, but the initial images were perplexing – normal left ventricle function, no evidence of systolic anterior motion, and nothing to suggest an LVOT obstruction.
Video
What is new in 2024 for PE
A comprehensive overview of strategic clinical risk stratification, evidence-based approaches derived from clinical trials and advanced research, and essential insights into the follow-up care of patients post-pulmonary embolism (PE).
Course
Breaking Down Updated Aortic Guidelines for Echocardiographers
In 2022, the American College of Cardiology and the American Heart Association released updated aortic guidelines that synthesized some 20 separate guidelines issued by nearly as many organizations over the previous 12 years.